OBJECTIVE To evaluate the safety of laparoscopic cholecystectomy (LC) in patients on oral anticoagulant therapy. METHODS Four patients were involved in this study on whom the procedure was performed in a conventional manner paying meticulous attention to haemostasis. The oral anticoagulant was resumed the night of the operation, and the patient was discharged and acceptable international norm...

The occurrence of venous thromboembolism complicates the management of the patient with malignant disease because of the need for anticoagulant therapy. Cancer patients have an ongoing thrombotic stimulus due to the underlying cancer and its associated treatments, but are also considered to be at increased risk for anticoagulant-related bleeding. In recent years, the results of clinical trials ...

Whether antithrombotic therapy in elderly patients differs from that in younger populations depends on whether the risk for such bleeding differs in the elderly. Regarding long-term therapy with warfarin derivatives, evidence shows that there is a difference. The anticoagulation response to warfarin is exaggerated with advancing age. This article discusses antithrombotic therapies for valvular ...

An amidolytic assay employing the chromogenic substrate S 2337 (Kabi Diagnostica) was used to assay factor X in 35 healthy controls and in 100 outpatients receiving oral anticoagulant therapy. This method correlated well with a coagulation assay of factor X in the control group (r = 0.88). When compared with two routine tests for the control of anticoagulant theray (Thrombotest and prothrombin ...

One hundred seventeen patients, 31 with TIA and 86 with cerebral infarction, had angiographically verified atherosclerosis within the relevant carotid artery territory and normal CSF. They were treated with anticoagulants for a mean of 11.1 months. No TIA but 1 cerebral infarction, appearing during inadequate anticoagulant therapy, was registered. Seventy-six of the patients, 20 with TIA and 56...

INTRODUCTION For patients with a first unprovoked venous thromboembolism (VTE), the optimal duration of anticoagulation is a crucial clinical dilemma which has yet to be resolved. The decision to stop anticoagulant therapy (AT) after the initial 3-6 months or to continue AT indefinitely, is primarily governed by the long-term risk of recurrence when treatment is discontinued. This risk however,...

This chapter about hemorrhagic complications of anticoagulant treatment is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Bleeding is the major complication of anticoagulant therapy. The criteria for defining the severity of bleeding varies considerably between studies, accounting in part for the variation in the rates of bleeding repo...

BACKGROUND Oral anticoagulation therapy is widely used to reduce the risks of thromboembolism. However, the therapy increases the risk of hemorrhage during the surgical procedures. The aim of this meta-analysis was to evaluate the bleeding risk of patients continuing or discontinuing oral anticoagulant therapy while undergoing dental extractions. METHODS Six electronic databases, including Pu...

OBJECTIVE To review the state of the art of laboratory monitoring of oral anticoagulant therapy, as reflected by the medical literature and the consensus opinion of recognized experts in the field, and to make recommendations for improvement in laboratory monitoring of oral anticoagulant therapy. DATA SOURCES Review of the medical literature, primarily from the last 10 years, and current labo...

Thrombosis is the leading cause of morbidity and mortality in the Western world. Arterial thrombosis leads to myocardial infarction and stroke. Arterial clots are platelet-rich and fibrin-poor (so-called white clots). They are generated at sites of vascular injury under high shear rates and are prevented or treated with antiplatelet drugs.1 However, because of the fact that the thrombin is a po...